Access

Format

Author / Creator

Subject

Recently added

Eresources

Language

Place of Publication

Dates

Location

I. Correspondence, 1815-1822. A. Letterbook, 1815-1822, being mainly reports to Messrs. Staniforth and Blunt, London, re shipping activities on board the Hebe, 1815-1819 and on board the Sesostris, 1820-1821, including 2 letters written from Sydney, 1815. A list of expenses for 1821 is at back of volume. B. Letters to, 1817, being instructions from Messrs. Staniforth and Blunt re shipping matters while in command of the ship Hebe. II. Genealogical notes, compiled 19--? re Porter and Pines families, 1853

James Porter papers, 1815-1853

Sub-series 1: Angus & Robertson book reviews in bound volumes, 1894-1970

Despite an ever-growing prevalence and increasing economic burden of Alzheimer’s disease (AD) and Parkinson’s disease (PD), recent advances in drug development have only resulted in minimally effective treatment. In AD, along with amyloid and tau phosphorylation, there is an associated increase in inflammation/glial activation, a decrease in synaptic function, an increase in astrocyte activation, and a state of insulin resistance. In PD, along with α-synuclein accumulation, there is associated inflammation, synaptic dysfunction, dopaminergic neuronal loss, and some data to suggest insulin resistance. Therapeutic strategies for neurodegenerative disorders have commonly targeted individual pathological processes. An effective treatment might require either utilization of multiple drugs which target the individual pathological processes which underlie the neurodegenerative disease or the use of a single agent which could influence multiple pathological processes. Insulin and incretins are compounds with multiple effects on neurodegenerative processes. Preclinical studies have demonstrated that GLP-1 receptor agonists reduce neuroinflammation, reduce tau phosphorylation, reduce amyloid deposition, increase synaptic function, and improve memory formation. Incretin mimetics may act through the restoration of insulin signaling pathways, inducing further neuroprotective effects. Currently, phase 2 and phase 3 trials are underway in AD and PD populations. Here, we provide a comprehensive review of the therapeutic potential of incretin mimetics and insulin in AD and PD.

Molecular psychiatry, 2023-01, Vol.28 (1), p.217-229

Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease

Export record to excel

Export this record

Export record to excel

James Porter papers, 1815-1853

Export this record

Export record to excel

Sub-series 1: Angus & Robertson book reviews in bound volumes, 1894-1970

Export this record

Export record to excel

Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease

Refine your search